AZ-4217 is a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. AZ-4217 has IC50 160 pM in human SH-SY5Y cells with an excellent in vivo efficacy. AZ-4217 may have potential for treatment of AD. BACE1 inhibition thus addresses a key mechanism in AD and its potential as a therapeutic target is currently being addressed in clinical studies. References: Eketjall S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesater AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlstrom S, Swahn BM, Falting J. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci. 2013 Jun 12;33(24):10075-84. doi: 10.1523/JNEUROSCI.1165-13.2013. PubMed PMID: 23761903.

纯度：≥98%

CAS：1383846-83-0